Cogent Biosciences (COGT)
(Delayed Data from NSDQ)
$9.27 USD
+0.13 (1.42%)
Updated Jul 12, 2024 04:00 PM ET
After-Market: $9.25 -0.02 (-0.22%) 6:30 PM ET
4-Sell of 5 4
D Value D Growth C Momentum F VGM
Brokerage Reports
Cogent Biosciences, Inc. [COGT]
Reports for Purchase
Showing records 61 - 80 ( 129 total )
Company: Cogent Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
The Sale Won''t Last Long with APEX Data Around the Corner
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Cogent Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: Cogent Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: Cogent Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Introduces ErbB2 at Investor Day; Tryptase Data Around the Corner
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Cogent Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: Cogent Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: Cogent Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
COGT Reports 4Q21; APEX Phase 2 on Track for 1H22 Initial Readout
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Cogent Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: Cogent Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
AACR 2022 Abstract Roundup For Covered Companies
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Cogent Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
AACR Poster Presentation Supports Bezuclastinib Safety and Selectivity; Debut of Novel Selective FGFR2 Inhibitors
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Cogent Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: Cogent Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Cogent Presents Year-End Update; Three Late-Stage Clinical Trials Underway
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Cogent Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
2022 Guidance Straight Forward and In-Line with Expectations
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Cogent Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Cogent Announces 3Q21 Earnings; New Phase 2 Launched; Other Clinical Programs on Track
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Cogent Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: Cogent Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: Cogent Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Qinlock Miss Opens the Door to Bezuclastinib in 2L GIST in Combo With Sutent
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Cogent Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: Cogent Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Building Another Best-in-Class Targeted Oncology Company With Bezuclastinib as Tip of the Spear; Initiate Buy and $25 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Cogent Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Relevant Abstracts at Upcoming EORTC-NCI-AACR Meeting
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D